Source-grounded facts extracted from Adaptive Biotechnologies Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Adaptive Biotechnologies Corp incurred senior notes of $345 million with U.S. Bank Trust Company, National Association at 0% maturing July 1, 2031.
“On June 22, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued $345 million in aggregate principal amount of 0% Convertible Senior Notes due 2031 (the “Notes”).”
Adaptive Biotechnologies Corp entered into Indenture with U.S. Bank Trust Company, National Association valued at $345 million (effective 2026-06-22).
“The Company issued the Notes pursuant to an indenture (the “Indenture”), dated as of June 22, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).”
Adaptive Biotechnologies Corp shareholders approved Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-05 meeting.
“Proposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2026”
Adaptive Biotechnologies Corp shareholders approved Advisory request concerning compensation for the Company's 2025 named executive officers at the 2026-06-05 meeting.
“Proposal 2: an advisory request concerning compensation for the Company's 2025 named executive officers”
Adaptive Biotechnologies Corp shareholders approved Election of two Class I directors to the Board of Directors (Robert Hershberg, PhD, MD and Katey Owen, PhD) at the 2026-06-05 meeting.
“Proposal 1: election of two Class I directors to the Board of Directors (Robert Hershberg, PhD, MD and Katey Owen, PhD)”
Adaptive Biotechnologies Corp updated its full year 2026 guidance (raised).
“Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.”
Adaptive Biotechnologies Corp reported the quarter ended March 31, 2026 results: revenue $70.9 million, net income $20.0 million.
“First Quarter 2026 Financial Results Revenue was $70.9 million for the quarter ended March 31, 2026, representing a 35% increase from the first quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended March 31, 2026, revenue for the current quarter increased 45% from the first quarter in the prior year. MRD revenue was $67.1 million for the quarter, representing a 53% increase from the first quarter in the prior year. Immune Medicine revenue was $3.8 million for the quarter, representing a 57% decrease from the first quarter in the prior year. Excluding revenue from the Genentech Agreement, Immune Medicine revenue for the quarter ended March 31, 2026 decreased 26% from the first quarter in the prior year. Operating expenses for the first quarter of 2026 were $90.1 million, compared to $82.0 million in the first quarter of the prior year, representing an increase of 10%. Interest and other income, net was”
Adaptive Biotechnologies Corp updated its full year 2024 guidance (lowered).
“Adaptive Biotechnologies expects full year revenue for the MRD business to be between $135 million and $140 million, updated from the previous range between $130 million and $140 million.”
Adaptive Biotechnologies Corp reported quarter ended March 31, 2024 results: revenue $41.9 million, net income $47.5 million loss.
“First Quarter 2024 Financial Results Revenue was $41.9 million for the quarter ended March 31, 2024, representing an 11% increase from the first quarter in the prior year. MRD revenue was $32.6 million for the quarter, representing a 52% increase from the first quarter in the prior year. Immune Medicine revenue was $9.2 million for the quarter, representing a 43% decrease from the first quarter in the prior year. Operating expenses were $90.6 million for the first quarter of 2024, compared to $94.8 million in the first quarter of the prior year, representing a decrease of 4%. MRD operating expenses were $59.9 million for the quarter, representing a 7% increase from the first quarter in the prior year. Immune Medicine operating expenses were $23.8 million for the quarter, representing a 25% decrease from the first quarter in the prior year. Interest and other income, net was $4.2 million for the first quarter of 2024, compared to $3.0 million in the first quarter of the prior year. Inte”
Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.
“As previously announced, Adaptive Biotechnologies Corporation (the “ Company ”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.”
Adaptive Biotechnologies Corp reported first quarter ended March 31, 2024 results: revenue approximately $41 to $43 million.
“process and outcome of the strategic review during the conference call this afternoon. First Quarter 2024 Preliminary Unaudited Revenue Results • Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023. • MRD revenue of approximately $31 to $32 million for the”
Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.
“Kyle Piskel, who has been with Company for 8 years and is currently its Principal Accounting Officer will serve as the Chief Financial Officer starting on April 8, 2024.”
Tycho Peterson resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.
“On April 1, 2024, the Chief Financial Officer of Adaptive Biotechnologies Corporation (the “ Company ”) Tycho Peterson submitted his resignation.”
Adaptive Biotechnologies Corp reported fiscal year 2024 results: revenue between $130 million and $140 million. Guidance initiated.
“2024 Financial Guidance Adaptive Biotechnologies expects full year revenue for the MRD business to be between $130 million and $140 million. No revenue guidance is provided for the Immune Medicine business. We expect full year operating expenses, including cost of revenue, to be between $360 million and $370 million.”
Adaptive Biotechnologies Corp reported full year ended December 31, 2023 results: revenue $170.3 million, net income Net loss was $225.3 million.
“Revenue was $170.3 million for the year ended December 31, 2023, representing an 8% decrease from the prior year. MRD revenue was $102.7 million in 2023, representing an 18% increase from the prior year. Immune Medicine revenue was $67.5 million in 2023, representing a 31% decrease from 2022. Operating expenses for 2023, which include a $25.4 million lease impairment charge, were $397.3 million, compared to $385.5 million for 2022, representing an increase of 3%. Excluding the impact of the lease impairment charge, operating expenses for 2023 decreased 4% compared to the prior year. Interest and other income, net was $15.5 million in 2023, compared to $4.1 million in 2022. Interest expense from our revenue interest purchase agreement was $13.8 million in 2023, compared to $4.2 million in 2022. Net loss was $225.3 million in 2023, compared to $200.4 million in 2022. Adjusted EBITDA (non-GAAP) was a loss of $116.4 million for 2023, compared to a loss of $121.6 million in the prior year.”
Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2023 results: revenue $45.8 million, net income Net loss was $69.5 million.
“Revenue was $45.8 million for the quarter ended December 31, 2023, representing a 17% decrease from the fourth quarter in the prior year. MRD revenue was $30.8 million for the quarter, representing a 9% increase from the fourth quarter in the prior year. Immune Medicine revenue was $15.0 million for the quarter, representing a 45% decrease from the fourth quarter in the prior year. Operating expenses, which include a $25.4 million lease impairment charge, were $116.9 million for the fourth quarter of 2023, compared to $94.4 million in the fourth quarter of the prior year, representing an increase of 24%. Excluding the impact of the lease impairment charge, operating expenses for the fourth quarter of 2023 decreased 3% compared to the fourth quarter of the prior year. Interest and other income, net was $4.6 million for the fourth quarter of 2023, compared to $2.6 million in the fourth quarter of the prior year. Interest expense from our revenue interest purchase agreement was $3.0 milli”
Adaptive Biotechnologies Corp reported the quarter ended September 30, 2023 results: revenue $37.9 million, net income $50.3 million. Guidance reaffirmed.
“Revenue was $37.9 million for the quarter ended September 30, 2023, representing a 21% decrease from the third quarter in the prior year.”
Kevin Conroy resigned as Director at Adaptive Biotechnologies Corp.
“On September 1, 2023, Adaptive Biotechnologies Corporation (the “ Company ”) Board of Directors (the “ Board ”) member Kevin Conroy submitted his resignation from the Board.”
Adaptive Biotechnologies Corp reported the quarter ended June 30, 2023 results: revenue $48.9 million, net income $47.8 million. Guidance reaffirmed.
“Immune Medicine businesses and we remain committed to driving operational efficiencies across the company while supporting sustainable growth.” Recent Highlights • Revenue of $48.9 million for the second quarter 2023, representing 12% growth from $43.7 million in the second quarter 2022. • clonoSEQ test volume in the second quarter 2023 grew 52% to 13,665 tests”
Nitin Sood resigned as Chief Commercial Officer of the MRD business at Adaptive Biotechnologies Corp.
“On July 28, 2023, the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity.”
Adaptive Biotechnologies Corp received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).
“June 26, 2023, the Company received a notice from Nasdaq regarding non-compliance with the rule requiring three members to serve on an Audit Committee and confirming the cure period applicable to the Company. The Company is evaluating the appropriate composition of its board committees and fully intends to regain compliance with Rule 5605(c)(2)(A) within the applicable cure period. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Adaptive Biotechnol”
Adaptive Biotechnologies Corp shareholders approved Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-09 meeting.
“Proposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2023 Votes Submitted As % of Proposal Votes Broker Non Vote For 121,162,529 99.72 % 0 Against 200,965 0.16 % Withhold/Abstain 138,671 0.11 %”
Adaptive Biotechnologies Corp shareholders approved Advisory vote concerning the 2022 compensation of the Company's named executive officers at the 2023-06-09 meeting.
“Proposal 2: Advisory Vote Concerning the 2022 Compensation of the Company's Named Executive Officers Votes Submitted As % of Proposal Votes Broker Non Vote For 89,592,587 82.68 % 13,147,625 Against 17,467,529 16.12 % Withhold/Abstain 1,294,424 1.19 %”
Adaptive Biotechnologies Corp shareholders approved Election of two Class 1 directors to the Board (Drs. Katey Owen and Robert Hershberg) at the 2023-06-09 meeting.
“Proposal 1: Election of Class 1 Directors Dr. Katey Owen Votes Submitted As % of Proposal Votes Broker Non Vote For 83,072,262 76.66 % 13,147,625 Against - - Withhold/Abstain 25,282,278 23.33 % Dr. Robert Hershberg Votes Submitted As % of Proposal Votes Broker Non Vote For 47,703,083 44.02 % 13,147,625 Against - - Withhold/Abstain 60,651,457 55.97 %”
Leslie Trigg resigned as Director at Adaptive Biotechnologies Corp.
“On June 9, 2023, Adaptive Biotechnologies Corporation (the " Company ") Board of Directors (the " Board ") member Leslie Trigg submitted her resignation from the Board.”
Adaptive Biotechnologies Corp reported the quarter ended March 31, 2023 results: revenue $37.6 million, net income Net loss was $57.7 million. Guidance reaffirmed.
“goals in both MRD and Immune Medicine and remain committed to drive operational efficiencies while managing capital allocation to support growth.” Recent Highlights • Revenue of $37.6 million for the first quarter 2023, representing a 3% decrease from $38.6 million in the first quarter 2022, which reflects the expected $3.2 million decline in amortization of the”
Mark Adams was terminated as Chief Operating Officer at Adaptive Biotechnologies Corp.
“On April 7, 2023, Mark Adams, Chief Operating Officer of Adaptive Biotechnologies Corporation (the “Company”), was informed that his service is being terminated by May 2023.”
Adaptive Biotechnologies Corp reported full year 2023 results: revenue $205 million to $215 million. Guidance initiated.
“Adaptive Biotechnologies expects full year 2023 revenue to be in the range of $205 million to $215 million.”
Adaptive Biotechnologies Corp reported full year ended December 31, 2022 results: revenue $185.3 million, net income Net loss was $200.4 million.
“Revenue was $185.3 million for the year ended December 31, 2022, representing a 20% increase from the prior year.”
Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2022 results: revenue $55.2 million, net income Net loss was $40.2 million.
“Revenue was $55.2 million for the quarter ended December 31, 2022, representing a 46% increase from the fourth quarter in the prior year.”
Adaptive Biotechnologies Corp updated its the quarter ended September 30, 2022 guidance (reaffirmed).
“On November 3, 2022, Adaptive Biotechnologies Corporation (the “ Company ”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2022.”
Tycho Peterson was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.
“On March 9, 2022, the Board of Directors of Adaptive Biotechnologies Corporation (the “ Company ”) appointed Tycho Peterson as Chief Financial Officer of the Company, effective upon his start date, no later than June 4, 2022 (the “ Effective Date ”).”
Kyle Piskel was appointed as Interim Chief Financial Officer at Adaptive Biotechnologies Corp.
“the Board of Directors of the Company appointed Mr. Kyle Piskel, the Company’s Principal Accounting Officer, as interim Chief Financial Officer effective concurrent with Mr. Cohen’s resignation”
Chad Cohen resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.
“the Company’s Chief Financial Officer, Mr. Chad Cohen, is resigning effective February 15, 2022”
Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.
“after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.”
Chad Cohen resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.
“On January 4, 2022, Chad Cohen, Chief Financial Officer of the Company, notified the Company of his decision to resign as Chief Financial Officer of the Company, effective following the filing of the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, on or about February 15, 2022, after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.”
Kyle Piskel was appointed as principal accounting officer at Adaptive Biotechnologies Corp.
“On October 28, 2021, the Board of Directors of the Company designated Kyle Piskel as the Company’s principal accounting officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.